20:41 , Oct 5, 2018 |  BC Week In Review  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
22:47 , Apr 24, 2018 |  BC Extra  |  Company News

Amgen considering risk-based Aimovig pricing

On a conference call to discuss 1Q18 earnings call, Amgen Inc. (NASDAQ:AMGN) EVP of Global Commercial Operation Anthony Hooper said the biopharma is "prepared to talk to payers about risk-based contracts with Aimovig." This quarter,...
21:16 , Apr 24, 2018 |  BC Extra  |  Company News

Biogen looks to ex-U.S. markets for growth

Biogen Inc. (NASDAQ:BIIB) perceives greater long-term growth opportunities than anticipated in the EU and emerging markets, the company's CEO Michel Vounatsos said on its earnings call Tuesday, while noting that the U.S. market remains its...
14:50 , Apr 6, 2018 |  BC Week In Review  |  Company News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi...
22:09 , Apr 5, 2018 |  BC Extra  |  Company News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
15:15 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

EC approves Bioepis' Humira biosimilar

Samsung Bioepis Co. Ltd. said the European Commission approved Imraldi (SB5), a biosimilar of autoimmune drug Humira adalimumab. The biosimilar is indicated to treat psoriasis, Crohn's disease, rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
19:07 , Jul 3, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends Imraldi biosimilar adalimumab

EMA’s CHMP recommended approval of Imraldi biosimilar adalimumab (SB5) from Samsung Bioepis Co. Ltd. to treat psoriasis and Crohn's disease (CD) in both adults and children, rheumatoid arthritis (RA), juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic...
22:38 , Jun 23, 2017 |  BC Extra  |  Company News

CHMP recommendations include two new HCV combos

On Friday, EMA's CHMP recommended approval of a basket of therapies, including two new combinations to treat HCV infection. The committee recommended approval of Maviret glecaprevir/pibrentasvir from AbbVie Inc. (NYSE:ABBV) to treat chronic HCV infection...